The City of Houston is aiming to have Arco del Tiempo installed in 2024. Photo courtesy of The City of Houston

The City of Houston has unveiled the first look at the latest permanent public artwork that will be installed in the Second Ward in 2024. The sculpture is the first-ever environmentally sustainable art piece that will generate electricity for the nearby City-owned Latino multicultural performing arts theater.

Arco del Tiempo (Arch of Time) is a 100-foot tall arch designed by Berlin-based artist and architect Riccardo Mariano. Several years have been put into the making of this project, dating as far back as 2019. Mariano had entered the idea into a Land Art Generator Initiative (LAGI) design competition in the Houston sister-city of Abu Dhabi. From there, it was chosen to be developed full-scale and installed at Guadalupe Plaza Park.

According to a press release, the sculpture can measure time and cast beams of sunlight onto the ground, creating a connection between "the celestial and the terrestrial" through the geometry of the design.

The light beams are different based on the four seasons and the time of day, constantly shifting and responding to the latitude and longitude of the city from space. Mariano said that his sculpture is a "practical example" of how physical art can interact with the abstract, such as the Earth's movement around the sun.

"The apparent movement of the sun in the sky activates the space with light and colors and engages viewers who participate in the creation of the work by their presence," said Mariano. "Arco del Tiempo merges renewable energy generation with public space and into the everyday life of the Second Ward. Inspired by science and powered by renewable energy, the artwork is a bridge between art and technology and encourages educational purposes while improving public space. At night the space within the arch will be used as a stage for outdoor public events.”

"At night the space within the arch will be used as a stage for outdoor public events,” Riccardo Mariano said.Photo courtesy of The City of Houston

Arco del Tiempo will do more than just be an aesthetically pleasing sight for the community. Its meaningful, functional purpose will be to generate about 400,000 kilowatt-hours of electricity per year, and power the Talento Bilingüe de Houston. LAGI founding co-director Elizabeth Monoian said in the release the sculpture will generate over 12 million kilowatt-hours of power throughout its lifetime, which equals the removal of 8,500 metric tons of carbon dioxide from the atmosphere.

"Through the clean energy it produces, Arco del Tiempo will pay back its embodied carbon footprint," Monoian said. "In other words, all the energy that went into its making—from the smelting of the steel to the drilling that puts the final cladding into place—will be offset through the energy it generates. Beyond its break-even point, which we will track and celebrate with the community, the artwork will be a net-positive contributor to a healthy climate and the planet will be better off for its existence.”

In a statement, Houston Mayor Sylvester Turner praised the unique art piece as more than just a sculpture, but as a "monument to a new era of energy."

"The City of Houston has always stood at the vanguard of energy innovation and the Arco del Tiempo artwork stands in that tradition, highlighting Houston’s role as an art city and as global leader in the energy transition," Mayor Turner said. "We are inspired by the vision and creative thinking. Marrying clean energy, the built environment, and truly World Class art is Houston.”

------

This article originally ran on CultureMap.

TXRX's new East End Space will allow them to provide prototyping and manufacturing services to more innovators. Courtesy of TXRX

Houston nonprofit makerspace seeking donations as it prepares to move into its new home

Calling for cash

With grants and public funds secured, Houston-based TXRX Labs as one last round of fundraising to acquire before it's ready to head full-speed ahead into its new location.

TXRX launched a $85,000 fundraising campaign to help get the organization where it needs to be before it moves into its 60,000-square-foot space in the East End Maker Hub in spring or summer of next year. The organization, along with its sister nonprofit, Urban Partnership Community Development Corp., has been selected by the city of Houston for an $18 million award and by the federal government for a $5 million innovation grant.

"In the last two weeks, we were getting close to finalizing funding for the building and came up short," says Lauren Caldarera, development director at TXRX. "We wanted to reach out to our membership at TXRX and the broader Houston community to help see if people will help support this unique offering for Houston."

In order to receive those grants, TXRX needs to submit design materials — a process that they budget to cost $325,000. (TXRX has already procured $240,000.) An anonymous donor agreed to match donations, and the organization has until the end of May to raise. Anyone can donate online.

TXRX is focused on bringing back Houston's East End as a manufacturing hub. As manufacturing jobs left the second, third, and fifth wards, it's created a need for skilled labor, middle class jobs, says Roland von Kurnatowski, executive director of TXRX.

"We're looking to bring together innovative companies in the physical innovation space into the East End and creating these middle class jobs," says von Kurnatowski. "It's a modern approach to combating economic inequalities instead of providing handouts."

TXRX is already making a dent in their mission with their smaller space. The organization has over 400 members and incubates 20 or so companies. The new space will allow TXRX to incubate almost twice that amount, work with 75 companies who need prototyping and manufacturing services, and grow their classes and educational offerings.

"Having this space is critical as Houston moves forward in creating an innovation ecosystem," Caldarera says. "We need a space for people to develop their physical prototypes, have engineers and other experts to coach and mentor them, and create more startups and innovators here."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston space company lands latest NASA deal to advance lunar logistics

To The Moon

Houston-based space exploration, infrastructure, and services company Intuitive Machines has secured about $2.5 million from NASA to study challenges related to carrying cargo on the company’s lunar lander and hauling cargo on the moon. The lander will be used for NASA’s Artemis missions to the moon and eventually to Mars.

“Intuitive Machines has been methodically working on executing lunar delivery, data transmission, and infrastructure service missions, making us uniquely positioned to provide strategies and concepts that may shape lunar logistics and mobility solutions for the Artemis generation,” Intuitive Machines CEO Steve Altemus says in a news release.

“We look forward to bringing our proven expertise together to deliver innovative solutions that establish capabilities on the [moon] and place deeper exploration within reach.”

Intuitive Machines will soon launch its lunar lander on a SpaceX Falcon 9 rocket to deliver NASA technology and science projects, along with commercial payloads, to the moon’s Mons Mouton plateau. Lift-off will happen at NASA’s Kennedy Space Center in Florida within a launch window that starts in late February. It’ll be the lander’s second trip to the moon.

In September, Intuitive Machines landed a deal with NASA that could be worth more than $4.8 billion.

Under the contract, Intuitive Machines will supply communication and navigation services for missions in the “near space” region, which extends from the earth’s surface to beyond the moon.

The five-year deal includes an option to add five years to the contract. The initial round of NASA funding runs through September 2029.

Play it back: Houston home tech startup begins 2025 with fresh funding

HOUSTON INNOVATORS PODCAST EPISODE 272

One of the dozen or so Houston startups kicking of the new year with fresh funding is SmartAC.com, a company that's designed a platform that enables contractors in the HVAC and plumbing industries to monitor, manage, and optimize their maintenance memberships through advanced sensors, AI-driven diagnostics, and proactive alerts.

Last month, the SmartAC.com raised a follow-on round with support from local investor Mercury to continue growth and expansion of the product, which has evolved on many ways since the company launched in 2020, emerging from stealth with $10 million raised in a series A. In a May 2023 interview for the Houston Innovators Podcast, Founder and CEO Josh Teekell explained how he embraced the power of a pivot.

The company's sensors can monitor all aspects of air conditioning units and report back any issues, meaning homeowners have quicker and less costly repairs. While SmartAC.com started with providing the service and tech to homeowners directly, Teekell says he's had a greater interest in working with plumbers and HVAC companies who then deploy the technology to their customers.

"It became quite evident that homeowners don't care about air conditioning really at all until their system breaks," Teekell says on the show. "The technology is really built around giving those contractors as another way to gain a customer relationship and keep it."

Revisit the podcast episode below where Teekell talks about SmartAC.com's last raise.

SmartAC.com's previous round in 2023 — a $22 million series B — was used grow its team that goes out to deploy the technology and train the contractors on the platform.

"We've been very fortunate to get some of the biggest names in Houston on our cap table," Teekell says in the May 2023 conversation. "Since we're raising a bunch of money locally, everyone understands what a pain air conditioning can be."

Houston biotech company tests hard-to-fight cancer therapeutics

fighting cancer

A Houston-based, female-founded biotech company has developed a treatment that could prove to be an effective therapy for a rare blood cancer.

Cellenkos Therapeutics has completed promising Phase 1b testing of its Treg cell therapy, CK0804, in the fight against myelofibrosis. According to a news release from the Cellenkos team, the use of its cord-blood-derived therapeutics could signal a paradigm shift for the treatment of this hard-to-fight cancer.

Cellenkos was founded by MD Anderson Cancer Center physician and professor Simrit Parmar. Her research at the hospital displayed the ability of a unique subset of T cells’ capability to home in on a patient’s bone marrow, restoring immune balance, and potentially halting disease progression.

Myelofibrosis has long been treated primarily with JAK (Janus Kinase) inhibitors, medications that help to block inflammatory enzymes. They work by suppressing the immune response to the blood cancer, but don’t slow the progression of the malady. And they’re not effective for every patient.

“There is a significant need for new therapeutic options for patients living with myelofibrosis who have suboptimal responses to approved JAK inhibitors,” Parmar says. “We are greatly encouraged by the safety profile and early signs of efficacy observed in this patient cohort and look forward to continuing our evaluation of the clinical potential of CK0804 in our planned expansion cohort.”

The expansion cohort is currently enrolling patients with myelofibrosis. What exactly are sufferers dealing with? Myelofibrosis is a chronic disease that causes bone marrow to form scar tissue. This makes it difficult for the body to produce normal blood cells, leaving patients with fatigue, spleen enlargement and night sweats.

Myelofibrosis is rare, with just 16,000 to 18,500 people affected in the United States. But for patients who don’t respond well to JAKs, the prognosis could mean a shorter span than the six-year median survival rate outlined for the disease by Cleveland Clinic.

Helping myelofibrosis patients to thrive isn’t the only goal for Cellenkos right now.

The company seeks to aid people with rare conditions, particularly inflammatory and autoimmune disorders, with the use of CK0804, but also other candidates including one known as CK0801. The latter drug has shown promising efficacy in aplastic anemia, including transfusion independence in treated patients.

The company closed its $15 million series A round led by BVCF Management, based in Shanghai, in 2021. Read more here.